Phase III study of BKM120/placebo with fulvestrant in postmenopausal patients with hormone receptor positive HER2-negative locally advanced or metastatic breast cancer refractory to aromatase inhibitor

Clinical trial summary: The purpose of this study is to determine whether the addition of daily BKM120 to fulvestrant is effective and safe in treating patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer refractory to aromatase inhibitor. Read more here.